AI Verdict
RAPH has stronger fundamentals based on our AI analysis.
RAPP vs RAPH Fundamental Comparison
| Metric | RAPP | RAPH |
|---|---|---|
| Revenue | N/A | N/A |
| Net Income | $-111.5M | $-1.3M |
| Net Margin | N/A | N/A |
| ROE | -23.0% | N/A |
| ROA | -21.8% | -2,413.2% |
| Current Ratio | 26.17x | 0.03x |
| Debt/Equity | 0.00x | N/A |
| EPS | $-2.86 | $0.07 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RAPP vs RAPH: Frequently Asked Questions
Is RAPP or RAPH a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RAPH has stronger fundamentals. RAPP is rated STRONG SELL (78% confidence) while RAPH is rated STRONG SELL (90% confidence). This is not investment advice.
How does RAPP compare to RAPH fundamentally?
Rapport Therapeutics, Inc. has ROE of -23.0% vs Raphael Pharmaceutical Inc.'s N/A. Net margins are N/A vs N/A respectively.
Which stock pays higher dividends, RAPP or RAPH?
RAPP has a dividend yield of N/A or no dividend while RAPH has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RAPP or RAPH for long term?
For long-term investing, consider that RAPP has STRONG SELL rating with 78% confidence, while RAPH has STRONG SELL rating with 90% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RAPP vs RAPH?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RAPP vs RAPH, the AI consensus favors RAPH based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.